Cytostatin, an inhibitor of cell adhesion to extracellular matrix, selectively inhibits protein phosphatase 2A  by Kawada, Manabu et al.
Cytostatin, an inhibitor of cell adhesion to extracellular matrix,
selectively inhibits protein phosphatase 2A
Manabu Kawada, Masahide Amemiya, Masaaki Ishizuka *, Tomio Takeuchi
Institute for Chemotherapy, M.C.R.F., 18-24 Miyamoto, Numazu-shi, Shizuoka 410-0301, Japan
Received 24 June 1999; received in revised form 6 September 1999; accepted 15 September 1999
Abstract
Cytostatin, which is isolated from a microbial cultured broth as a low molecular weight inhibitor of cell adhesion to
extracellular matrix (ECM), has anti-metastatic activity against B16 melanoma cells in vivo. In this study, we examined a
target of cytostatin inhibiting cell adhesion to ECM. Cytostatin inhibited tyrosine phosphorylation of focal adhesion kinase
(FAK) and paxillin upon B16 cell adhesion to fibronectin. While the amount of FAK was not affected by cytostatin,
electrophoretically slow-migrating paxillin appeared. Alkaline phosphatase treatment diminished cytostatin-induced slow-
migrating paxillin. Furthermore, cytostatin increased intracellular serine/threonine-phosphorylated proteins and was found
to be a selective inhibitor of protein phosphatase 2A (PP2A). Cytostatin inhibited PP2A with an IC50 of 0.09 Wg/ml in a non-
competitive manner against a substrate, p-nitrophenyl phosphate, but it had no apparent effect on other protein
phosphatases including PP1, PP2B and alkaline phosphatase even at 100 Wg/ml. On the contrary, dephosphocytostatin, a
cytostatin analogue, without inhibitory effect on PP2A did not affect B16 cell adhesion including FAK and paxillin. These
results indicate that cytostatin inhibits cell adhesion through modification of focal contact proteins such as paxillin by
inhibiting a PP2A type protein serine/threonine phosphatase. This is the first report that describes a drug with anti-metastatic
ability that inhibits PP2A selectively. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Cell adhesion to extracellular matrix (ECM) in-
volves in the regulation of many biological processes
including immunity, development and tumor growth.
In the processes of tumor metastasis, cancer cell ad-
hesion to ECM is thought to be one of the targets for
anti-metastatic therapy. The cell adhesion to ECM is
controlled by many molecules. Integrins act as cell
surface receptors for ECM. While integrins them-
selves have no intrinsic kinase activity, they function
through interacting with a number of other proteins.
Upon their binding to ECM, they aggregate, assem-
ble several proteins and form a focal contact, in
which actin-containing cytoskeleton links structurally
[1,2]. The focal contact consists of structural proteins
such as vinculin, talin and actin and protein tyrosine
kinases such as focal adhesion kinase (FAK) and src,
as well as adapter proteins such as paxillin and crk.
Phosphorylation and dephosphorylation of these
protein components regulate assembly of the focal
contact and transduce the cell adhesion signals intra-
cellularly. Among them, tyrosine phosphorylations
of FAK and paxillin by cell adhesions are well
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known events for connecting the integrins and actin
stress ¢ber [1,3^5].
Cytostatin (Fig. 1) is originally isolated as a novel
inhibitor of cell adhesion to ECM from cultured
broth of Streptomyces sp. MJ654-NF4 [6,7]. Cyto-
statin has an anti-metastatic ability and inhibits ex-
perimental and spontaneous lung metastasis of B16
cells in mice [6,8]. Furthermore, cytostatin inhibits
growth of various tumor cell lines in vitro and in-
duces apoptosis in some cell lines [6,9,10]. To under-
stand the mechanism(s) of cytostatin actions on
metastasis and apoptosis, we investigated a primary
target of cytostatin in this study focusing on cell
adhesion. As a result, we have found that cytostatin
selectively inhibits protein serine/threonine phospha-
tase 2A (PP2A).
2. Materials and methods
2.1. Reagents and antibodies
Cytostatin and dephosphorylated cytostatin were
prepared as described [6,7]. Calyculin A was ob-
tained from Gibco BRL (Gaithersburg, MD, USA).
PP1 (14-110) and PP2A (14-111) were from Upstate
Biotechnology (Lake Placid, NY, USA). PP2B and
calmodulin were from Sigma (St. Louis, MO, USA).
Calf intestine alkaline phosphatase (CIAP) was from
Biozyme (South Wales, UK). Antibodies used for
Western blotting were the following: anti-phospho-
tyrosine (05-321) was from Upstate Biotechnology,
anti-FAK (F15020) and paxillin (P13520) were
from Transduction Laboratories (Lexington, KY,
USA), anti-phosphoserine (61-8100) and phospho-
threonine (71-8200) were from Zymed (South San
Francisco, CA, USA), anti-vinculin (V4505) and K-
actinin (A2534) were from Sigma.
2.2. Cells
Mouse B16 melanoma cells were maintained in
Dulbecco’s modi¢ed Eagle’s medium supplemented
with 10% fetal bovine serum (JRH Biosciences, Le-
nexa, KS, USA), 100 U/ml penicillin G and 100 Wg/
ml streptomycin at 37‡C with 5% CO2.
2.3. Cell adhesion to ¢bronectin (FN)
As reported previously [6,11], FN-coated plates
were prepared and the cell adhesion assay was per-
formed. B16 cells were inoculated into the FN-coated
plates and incubated with or without test chemicals
for 1 h at 37‡C. The plates were washed with phos-
phate-bu¡ered saline (PBS), ¢xed with glutaralde-
hyde and stained with crystal violet. In the case of
Western blotting, the cells including adhered and un-
adhered ones were collected after 1 h incubation at
37‡C.
2.4. Preparation of cell lysates and Western blotting
Treated cells were washed twice with ice-cold PBS
containing 100 WM Na3VO4 and then lysed in a lysis
bu¡er (20 mM HEPES (pH 7.5), 150 mM NaCl, 1%
Triton X-100, 10% glycerol, 1 mM EDTA, 50 mM
NaF, 50 mM L-glycerophosphate, 1 mM Na3VO4
and 25 Wg/ml each of antipain, leupeptin and pepsta-
tin). Equal protein extracts were separated by so-
dium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE) and transferred onto Immobilon
PVDF membranes (Millipore, Bedford, MA, USA).
Enhanced chemiluminescence (Amersham, Arlington
Heights, IL, USA) was used to visualize the immu-
noblot signals.
2.5. Immunoprecipitation
Cell lysates were prepared as described above and
equal amounts of protein were incubated with anti-
FAK (F15020) or anti-paxillin (P13520) from Trans-
duction Laboratories. The immune complexes were
collected on protein A-Sepharose beads (Pharmacia
Biotech, Piscataway, NJ, USA) pretreated with anti-
mouse IgG and washed four times in IP bu¡er (20
mM HEPES (pH 7.5), 150 mM NaCl, 1% Triton X-
100, 1 mM EDTA, 50 mM NaF, 50 mM L-glycero-
phosphate, 0.1 mM PMSF and 0.2 mM Na3VO4)
and once in a bu¡er containing 20 mM HEPES
(pH 7.5), 10 mM MgCl2 and 1 mM DTT. The im-
munoprecipitates were separated by SDS-PAGE and
immunoblotted as described above.
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2.6. Alkaline phosphatase treatment of
immunoprecipitated paxillin
Cell lysates were immunoprecipitated with anti-
paxillin as described above. The immunoprecipitates
were incubated in a phosphatase bu¡er containing 20
mM HEPES (pH 10), 10 mM MgCl2, 1 mM DTT
and 0.1 mg/ml CIAP for 30 min at 37‡C and this
procedure was then repeated twice. The treated im-
munoprecipitates were analyzed by immunoblotting.
2.7. Protein phosphatase assay
PP1 (0.05 U), PP2A (0.05 U) or CIAP (10 Wg/ml)
was incubated with 5 mM p-nitrophenyl phosphate
(PNPP; Research Organics, Cleveland, OH, USA) as
a substrate in a bu¡er (100 Wl) containing 20 mM
HEPES (pH 7.5), 10 mM MgCl2 and 1 mM DTT
for 1 h. PP2B activity was assessed as described by
Honkanen [12]. PP2B (0.5 U) was incubated with
5 mM PNPP in a bu¡er (100 Wl) containing 50 mM
Fig. 1. Structures of cytostatin and dephosphocytostatin.
Fig. 2. E¡ect of cytostatin on B16 cell adhesion to FN. B16 cells were inoculated into a plate pre-coated with none or FN and then
incubated with or without 10 Wg/ml cytostatin for 1 h at 37‡C.
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Tris-HCl (pH 8.5), 20 mM MgCl2, 0.25 mM DTT,
0.1 mM CaCl2 and calmodulin (50 U). The absorb-
ance of released p-nitrophenol was determined at 405
nm in a microtiter plate reader.
3. Results
3.1. Cytostatin inhibits intracellular signals of cell
adhesion
When B16 cells were plated on a FN-coated plate,
the cells were well spread. But by the addition of
cytostatin at 10 Wg/ml, the cells were rounded and
inhibited to spread out on a plate (Fig. 2). It is
well known that focal contact proteins such as
FAK and paxillin are phosphorylated at tyrosine
residues when cells adhere to FN [3^5]. As shown
in Fig. 3, when B16 cells were plated on a FN-coated
plate for 1 h, some proteins (V70 kDa) were
strongly tyrosine-phosphorylated. Furthermore,
when FAK and paxillin were immunoprecipitated,
they were found to be also strongly tyrosine-phos-
phorylated. Cytostatin at 10 Wg/ml inhibited the ty-
rosine phosphorylation of those proteins including
FAK and paxillin completely (Fig. 3). These results
indicated that cytostatin inhibited the intracellular
signals of cell adhesion.
3.2. Modi¢cation of paxillin by cytostatin
Although cytostatin did not a¡ect the amounts of
FAK, vinculin and K-actinin (Fig. 3 and data not
shown), it a¡ected paxillin even in the cells on a
Fig. 3. E¡ect of cytostatin on cell adhesion signals. B16 cells
were inoculated into a plate pre-coated with none or FN and
then incubated with or without 10 Wg/ml cytostatin (CTS) for
1 h at 37‡C. Cell lysates were prepared and Western blotting
was done using the indicated antibodies. For tyrosine-phos-
phorylated FAK and paxillin, the cell lysates were immunopre-
cipitated with anti-FAK or anti-paxillin antibody and immuno-
blotted with anti-phosphotyrosine antibody.
Fig. 4. Phosphorylation of paxillin by cytostatin. B16 cells were inoculated into a plate pre-coated with FN and then incubated with
10 Wg/ml cytostatin (CTS) or 0.1 Wg/ml calyculin A (CLA) for 1 h at 37‡C. (Left) Cell lysates were prepared and immunoblotted with
anti-paxillin antibody. (Right) Cell lysates were immunoprecipitated with anti-paxillin antibody, treated with alkaline phosphatase
(CIAP) and immunoblotted with anti-paxillin antibody.
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non-coated plate. Electrophoretically slow-migrating
bands of paxillin on SDS-PAGE appeared by 1 h
treatment of cytostatin (Fig. 3).
It is reported that paxillin is retarded electropho-
retically by both phosphorylation at serine residues
and dephosphorylation at tyrosine residues and de-
phosphorylation of the slow-migrating paxillin by
alkaline phosphatase restores its mobility on SDS-
PAGE [13,14]. We looked into the possibility that
cytostatin could a¡ect paxillin through serine/threo-
nine phosphorylation comparing a serine/threonine
phosphatase inhibitor, calyculin A. As a result, caly-
culin A at 0.1 Wg/ml retarded paxillin on SDS-PAGE
more strongly than cytostatin at 10 Wg/ml did (Fig.
4). When paxillin was immunoprecipitated and then
treated with alkaline phosphatase, both cytostatin-
and calyculin A-induced slow-migrating paxillins
were disappeared (Fig. 4). Furthermore, a normal
Fig. 5. Inhibition of PP2A by cytostatin. (A) Puri¢ed PP1 (b), PP2A (F) or PP2B (R) was incubated with PNPP in the presence of
the indicated concentrations of cytostatin. The phosphatase activities were assessed as described in Section 2. (B) Lineweaver-Burk
plot of PP2A. PP2A was incubated with 0 (a), 0.125 (b), 0.25 (F) and 0.5 (R) Wg/ml cytostatin or 0.01 (b) and 0.02 (F) Wg/ml caly-
culin A and the kinetic study was done. Km for control, 3.4 mM; Ki for cytostatin, 0.3 Wg/ml (0.7 WM); Ki for calyculin A, 16 ng/ml
(0.016 WM). The values were representative results of three independent duplicate determinations. Each S.E.M. is less than 10%.
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mobility band of paxillin was decreased by both
drugs, especially by calyculin A (Fig. 4). These re-
sults suggested that cytostatin as well as calyculin A
modi¢ed paxillin through serine or threonine phos-
phorylation and decreased it.
3.3. Cytostatin selectively inhibits PP2A
non-competitively
To ascertain the possibility that cytostatin could
inhibit a serine/threonine phosphatase like calyculin
A, the e¡ect of cytostatin on the activities of various
protein phosphatases was examined. As shown in
Fig. 5A and Table 1, although cytostatin did not
a¡ect the activities of PP1, PP2B and alkaline phos-
phatase even at 100 Wg/ml, it inhibited PP2A dose-
dependently with an IC50 of 0.09 Wg/ml (0.21 WM).
Compared with other protein phosphatase inhibitors,
calyculin A and okadaic acid [15], they inhibited
PP2A and PP1 at lower concentrations than that of
cytostatin (Table 1). However, cytostatin was found
to inhibit PP2A selectively more than calyculin A
and okadaic acid and its selectivity was more than
1000 times against PP2A compared with PP1 (Table
1). Thus, cytostatin is rather a selective inhibitor of
PP2A. Because of its selectivity, it was suggested that
cytostatin inhibited PP2A uniquely. Then, its inhib-
itory kinetics was examined compared with that of
calyculin A. While a Lineweaver-Burk plot repre-
sented that calyculin A inhibited PP2A competitively
with a substrate, that of cytostatin was revealed to be
a non-competitive manner with a substrate (Fig. 5B).
These results indicated that cytostatin inhibited
PP2A selectively with a unique mechanism.
3.4. Cytostatin accumulates serine/threonine-
phosphorylated proteins
Because it is suggested that cytostatin could inhibit
intracellular serine/threonine phosphatase, the e¡ect
of cytostatin on intracellular serine and threonine
phosphorylations of proteins using speci¢c antibod-
ies to phosphoserine and phosphothreonine was ex-
amined. Although B16 cell adhesion to a FN-coated
Table 1
E¡ect of various compounds on protein phosphatases
PP1 IC50 (WM) PP2A IC50 (WM) PP1/PP2A folda PP2B IC50 (WM) Alkaline phosphatase IC50 (WM)
Cytostatin s 250 0.21 s 1 000 s 250 s 250
DephCTSb n.d.c s 250 n.d. n.d. n.d.
Calyculin A 0.04 0.004 10 n.d. n.d.
Okadaic acid 0.005 0.0004 13 n.d. n.d.
Inhibitory e¡ects of cytostatin, calyculin A and okadaic acid against PP1, PP2A, PP2B or alkaline phosphatase activity were assessed
as decribed in Section 2.
aIC50 in PP1 is divided by IC50 in PP2A.
bDephosphocytostatin.
cNot determined.
Fig. 6. Increase of serine/threonine-phosphorylated proteins by
cytostatin. B16 cells were inoculated into a plate pre-coated
with FN and then incubated with 10 Wg/ml cytostatin (CTS) for
1 h at 37‡C. Cell lysates were prepared and immunoblotted
with anti-phosphoserine (P-Ser) or anti-phosphothreonine (P-
Thr) antibody.
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plate did not apparently a¡ect intracellular serine
and threonine phosphorylations, cytostatin as ex-
pected increased both phosphorylated proteins, espe-
cially threonine-phosphorylated ones (Fig. 6). These
results indicated that cytostatin inhibited intracellu-
lar serine/threonine phosphatase.
Fig. 7. E¡ect of dephosphocytostatin on PP2A and B16 cell adhesion. (A) Morphology of B16 cells on a FN-coated plate. The cells
were incubated with 10 Wg/ml cytostatin (CTS) or dephosphocytostatin (DephCTS) for 1 h at 37‡C. (B) E¡ect of dephosphocytostatin
on cell adhesion signals. B16 cells were incubated on a FN-coated plate with 10 Wg/ml of cytostatin (CTS) or dephosphocytostatin
(DephCTS) for 1 h at 37‡C. Western blotting was performed as described in Figs. 3 and 5.
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3.5. Inhibition of PP2A by cytostatin a¡ects B16 cell
adhesion
It is reported that dephosphorylation of calyculin
A reduces its phosphatase inhibitory activity [16].
Like calyculin A, a dephosphorylated cytostatin, de-
phosphocytostatin, lost its inhibitory activity against
PP2A (Table 1). To con¢rm that cytostatin a¡ects
B16 cell adhesion through inhibition of PP2A, the
e¡ect of dephosphocytostatin on cell adhesion was
examined compared with cytostatin. As a result, de-
phosphocytostatin did not a¡ect cell adhesion and
intracellular tyrosine phosphorylation including
FAK and paxillin (Fig. 7). Furthermore, it did not
increase intracellular serine/threonine phosphoryla-
tion and a¡ect paxillin (Fig. 7B and data not shown).
Thus, these results indicated that inhibition of PP2A
by cytostatin a¡ected the cell adhesion.
4. Discussion
Cytostatin induced cell rounding and inhibited the
tyrosine phosphorylation of FAK and paxillin (Fig.
3). However, cytochalasin D, a cytoskeletal actin in-
hibitor, and herbimycin A, a tyrosine kinase inhibi-
tor, did not induce electrophoretically slow-migrating
paxillin (data not shown). Furthermore, cytostatin
did not inhibit various protein kinases such as pro-
tein tyrosine kinase, protein kinase C and protein
tyrosine phosphatase (data not shown). Thus, only
actin ¢ber inhibition or tyrosine kinase inhibition
could not a¡ect paxillin. It is reported that during
mitosis, paxillin is phosphorylated primarily on ser-
ine and dephosphorylated on tyrosine and becomes
electrophoretically slow-migrating [13]. Although ca-
lyculin A was not reported to a¡ect paxillin [14],
both cytostatin and calyculin A were found to mod-
ify paxillin through serine/threonine phosphorylation
and decrease the protein levels (Fig. 4). Paxillin is
known to be important in connecting the integrin
with actin ¢ber, via interacting with various mole-
cules such as vinculin, talin and FAK [1,2]. In fact,
it is reported that papillomavirus E6 oncoprotein
binds to paxillin and disrupts actin ¢ber formation,
indicating the critical role of paxillin in the mainte-
nance of the actin cytoskeletal network [17]. Thus,
changes in phosphorylation and protein levels of
paxillin by cytostatin may disrupt the organization
of focal contact and then decrease intracellular tyro-
sine phosphorylation.
In the course of studying the mechanism of cyto-
statin action, we have found that cytostatin is a selec-
tive inhibitor of PP2A. For the interaction between
paxillin and PP2A, it is still unknown whether PP2A
dephosphorylates paxillin directly in vivo. To under-
stand the role of PP2A in cell adhesion more pre-
cisely, we are now studying it in detail. For the in-
hibition of PP2A by cytostatin, the kinetic study
revealed that cytostatin inhibited PP2A non-compet-
itively with a substrate unlike calyculin A (Fig. 5B).
This unique inhibitory action on PP2A may result in
its selectivity. We have investigated the other related
compound to cytostatin in a data base and found
that phoslactomycin and fostriecin, structurally sim-
ilar compounds to cytostatin, also inhibit PP2A [18^
21]. Although fostriecin is reported to suppress tu-
mor growth in vivo [22], whether these related com-
pounds also have anti-metastatic activities in vivo
has not been reported yet. Thus, this is the ¢rst re-
port that describes an anti-metastatic compound that
inhibits PP2A selectively. Although we are now
studying the precise mechanism by which cytostatin
inhibits cancer metastasis in vivo, our results suggest
the possible involvement of PP2A in cancer metasta-
sis.
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